0000000000911582

AUTHOR

Sigrun Halvorsen

showing 4 related works from this author

Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology

2021

Background. Heart rhythm disorders, especially atrial fibrillation (AF), are increasing global health challenges. Conventional diagnostic tools for assessment of rhythm disorders suffer from limited availability, limited test duration time, and usability challenges. There is also a need for out-of-hospital investigation of arrhythmias. Therefore, the Norwegian ECG247 Smart Heart Sensor has been developed to simplify the assessment of heart rhythm disorders. The current study aimed to evaluate the diagnostic accuracy and usability of the ECG247 Smart Heart Sensor compared to conventional Holter monitors. Methods. Parallel tests with ECG247 Smart Heart Sensor and a Holter monitor were perform…

MaleMedicine (General)TechnologyHolter monitormedicine.medical_specialtyRhythm analysisArticle SubjectHeart rhythm disordersBiomedical EngineeringHealth InformaticsDiagnostic accuracyDiagnostic toolsElectrocardiographyR5-920Heart RateAtrial FibrillationMedical technologymedicineHumansR855-855.5medicine.diagnostic_testbusiness.industryAtrial fibrillationUsabilityMiddle Agedmedicine.diseaseTest durationEmergency medicineElectrocardiography AmbulatoryFemaleSurgerybusinessResearch ArticleBiotechnologyJournal of Healthcare Engineering
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct